Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,673 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo oral capsules Clear all
Completed Phase 4 Interventional Results available

Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)

NCT01517711
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Tramadol, Placebo
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of a Hypolipidemic Agent in Healthy Normal Volunteers

NCT00685737
View directory record Official record
Conditions
Hyperlipidemia
Interventions
1-MNA, Placebo
Drug
Lead sponsor
Pharmena North America
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2008 · Synced Oct 16, 2026, 4:43 AM EDT
Recruiting Phase 2 Interventional

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

NCT06937307
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Interventions
Droxidopa capsules, Placebo
Drug · Other
Lead sponsor
Giuseppe Cullaro, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 4 Interventional Results available

A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

NCT03922945
View directory record Official record
Conditions
Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
Interventions
VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification
Drug · Behavioral
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 16 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norman, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 3 Interventional

PRC-063 in an ADULT Workplace Environment

NCT02225639
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
PRC-063 25 mg, Placebo, PRC-063 35 mg, PRC-063 45 mg, PRC-063 55 mg, PRC-063 70 mg, PRC-063 85 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Newport Beach, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

NCT06164951
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

NCT03374475
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922 20mg, JNJ-42847922 40mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
San Diego, California • San Marcos, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

NCT04154501
View directory record Official record
Conditions
Chronic Pain, Nociceptive Pain, Pain
Interventions
CNTX-6016, Other: Placebo
Drug · Other
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 16, 2026, 4:43 AM EDT
Not listed Phase 2 Interventional

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

NCT03542851
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Pentetrazol (PTZ), Placebo oral capsule
Drug
Lead sponsor
Balance Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 16, 2026, 4:43 AM EDT
Not listed Phase 1Phase 2 Interventional

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

NCT04815902
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Fisetin, Losartan, Placebo - Losartan, Placebo Fisetin
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
40 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT04795037
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo
Drug
Lead sponsor
Curacle Co., Ltd.
Industry
Eligibility
19 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 16, 2026, 4:43 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Blocking Mifepristone Action With Progesterone

NCT03774745
View directory record Official record
Conditions
Pregnancy, Unwanted
Interventions
Mifepristone 200 MG, micronized Progesterone, Placebo oral capsule
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 16, 2026, 4:43 AM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

NCT04729595
View directory record Official record
Conditions
Covid19
Interventions
Tempol, Placebo
Drug · Other
Lead sponsor
Adamis Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Anniston, Alabama • Los Angeles, California • Doral, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 16, 2026, 4:43 AM EDT
Terminated Early Phase 1 Interventional Results available

Cardiometabolic Disease and Pulmonary Hypertension

NCT03349775
View directory record Official record
Conditions
Obesity
Interventions
Metformin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 16, 2026, 4:43 AM EDT
Terminated Not applicable Interventional Results available

Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

NCT00183430
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, Sleep Initiation and Maintenance Disorders
Interventions
Prazosin, Placebo, Psychotherapy
Drug · Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

NCT06804603
View directory record Official record
Conditions
Obesity
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 16, 2026, 4:43 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

NCT05997641
View directory record Official record
Conditions
Healthy, Safety and Tolerability
Interventions
DF-003, Placebo
Drug
Lead sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

NCT02706951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 16, 2026, 4:43 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise

NCT03540602
View directory record Official record
Conditions
Muscle Soreness
Interventions
Tart Cherry, Placebo Oral Capsule [CEBOCAP]
Dietary Supplement · Other
Lead sponsor
Jacksonville University
Other
Eligibility
21 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 16, 2026, 4:43 AM EDT
Withdrawn Phase 2Phase 3 Interventional

GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression

NCT05482672
View directory record Official record
Conditions
Knee Osteoarthritis, Obese, Depression
Interventions
Fisetin, GetHealthy-OA mind-body program, Placebo oral capsule, Health education booklet
Drug · Behavioral
Lead sponsor
Cale Andrew Jacobs, PhD
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Behavioral Effects of Drugs: Inpatient (35)

NCT03519022
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cocaine, Placebo oral capsule, Methylphenidate
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

NCT00954356
View directory record Official record
Conditions
Dental Pain
Interventions
XPF-001, placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

NCT05405114
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 16, 2026, 4:43 AM EDT